Production (Stage)
Navco Pharmaceuticals Inc.
NAV.V
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 37.75% | 20.63% | 113.84% | -907.25% | -- |
| Total Depreciation and Amortization | 42.64% | 65.95% | 95.57% | 90.17% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -10.85% | -11.02% | -161.84% | 7,342.86% | -- |
| Change in Net Operating Assets | 168.18% | 186.68% | 188.64% | -262.48% | -- |
| Cash from Operations | 94.70% | 85.91% | 47.68% | -3,619.76% | -- |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | 648.00% | -- | -- |
| Total Debt Repaid | 60.76% | 72.80% | 76.02% | 13.89% | -- |
| Issuance of Common Stock | -- | -- | -100.00% | -63.83% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -1,176.19% | -- | -- |
| Cash from Financing | -98.68% | -98.72% | -101.49% | -67.53% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -246.82% | -201.39% | -199.66% | -199.19% | -- |